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HTLV-I is considered to be a virus of low morbidity, since the principal diseases associated with this viral infection, HTLV-I–
associated myelopathy/tropical spastic paraparesis (HAM/TSP) and adult T-cell leukemia/lymphoma (ATLL), are observed in
less than 5% of infected individuals. Urinary symptoms are frequent in patients with myelopathy and consist principally of
nocturia, frequency, urgency, and urinary incontinence; however, the importance of these dysfunctions and their correlation with
myelopathy is still to be fully clarified. This review gives particular emphasis to the high frequency of urinary and sexual complaints
not only in patients with myelopathy but also in individuals considered to be HTLV-I carriers. Detrusor overactivity and bladder-
sphincter dyssynergia are the most common urodynamic findings. The fact that urinary complaints and urodynamic parameters
reported in individuals considered to be carriers are similar to those detected in patients with myelopathy supports the hypothesis
that urinary disorders may represent an oligosymptomatic form of HAM/TSP. Erectile dysfunction is frequently observed in
HTLV-I–infected patients with or without myelopathy. Urinary tract infections are also highly prevalent in these patients. Despite
the lack of an effective treatment for myelopathy, the use of anticholinergic drugs and phosphodiesterase type 5 (PDE5) inhibitors
may improve urinary complaints and erectile dysfunction in these patients.
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INTRODUCTION
The human T-cell lymphotropic virus type 1 (HTLV-I)
is a retrovirus of the Retroviridae family and the
Oncovirinae subfamily. It is the etiological agent of HTLV-
I–associated myelopathy/tropical spastic paraparesis (HAM/
TSP)1 and of adult T-cell leukemia/lymphoma (ATL).2
Around 20 million individuals worldwide are estimated to
be infected with this virus, and of these, approximately 5%
will develop ATL2 or HAM/TSP.1 Additionally, in our co-
hort at the HTLV-I clinic of the Hospital Universitário Pro-
fessor Edgard Santos, up to 40% of HTLV-I–infected indi-
viduals have urinary manifestations, arthralgia or arthro-
sis, sicca syndrome, chronic periodontitis, or erectile dys-
function. However, although other diseases are associated
with HTLV-I, most individuals infected are considered to
be asymptomatic carriers of the virus.
Central Africa, Japan, the Caribbean, South America,
and Melanesia are the principal endemic areas for HTLV-
I.3 Although the viral infection is prevalent in Brazil and
testing of blood products for HTLV-I has been mandatory
since 1993, the level of knowledge of healthcare profes-
sionals with respect to the virus in general falls short of
ideal.4 The epidemiology of HTLV-I in Brazil is important,
the infection being detected serologically in blood donors
in every region of the country, and particularly in the states
of Maranhão, Bahia, Pernambuco and Pará.5 The highest
seroprevalence in the country (1.8%) was found in the city
of Salvador in the state of Bahia.6 The same study found
positive HTLV-I serology in 18.4% of patients hospitalized
in an infectious disease unit. Another population-based
study carried out in the same city reported a prevalence of
1.7% of infected individuals.7 In Brazil, an alarming
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number of individuals (2,500,000) are believed to be in-
fected by HTLV-I.8 In the United States of America, 46,000
individuals are estimated to be infected with HTLV-I and
220,000 with HTLV-II.9 In the city of Nagasaki, Japan,
more than 10% of the adult population above 40 years of
age is seropositive for HTLV-I.10
HTLV may be transmitted vertically (mother-to-child)
through breastfeeding, and around 27% of newborn infants
breast-fed for more than 3 months by seropositive moth-
ers acquire the infection.4 Intrauterine transmission and in-
trapartum transmission in the birth canal may occur in up
to 5% of seropositive mothers.11 Horizontal transmission
occurs as a result of sexual intercourse with a seropositive
individual, male-to-female transmission being the most fre-
quent, as well as through blood transfusion and the use of
injectable drugs via contaminated syringes or needles.
Some investigators have reported that the infection acquired
through a contaminated blood transfusion has been asso-
ciated with the development of a more abrupt and intense
state of myelopathy; however, others dispute this finding.3,4
HTLV has lower infectivity and a longer incubation time
than HIV.
Diagnosis of the infection is generally made following
serological screening tests using the ELISA technique, posi-
tive cases being confirmed by Western blot (WB) or
polymerase chain reaction (PCR) whenever WB is incon-
clusive. In Brazil, serological testing has been mandatory
at all blood banks since 1993.
It is, therefore, important to acquire more knowledge
about this viral infection, since its presence may be involved
in several clinical findings associated with dermatological,
rheumatological, neurological, ophthalmological, clinical,
immunological, and urological disorders that result from se-
ropositivity and HAM/TSP. In this review, emphasis is given
to the urinary and sexual manifestations associated with
HTLV-I infection, stressing the possibility of the existence
of lesions to the medulla that may lead to an
oligosymptomatic form of myelopathy caused by this virus.
Pathogenesis and clinical manifestations of HAM/TSP
Around 5% of individuals infected by HTLV-I will go
on to develop ATL or a progressive stage of inflammatory
and demyelinating myelopathy known as HAM/TSP; its
physiopathology has not yet been completely clarified.
Nevertheless, as in other diseases associated with HTLV-I,
the immune response plays a fundamental role in this proc-
ess. The predilection of the virus for T-lymphocytes is well
known, although macrophages, B-lymphocytes, and other
cells may also be infected by HTLV-I. In these cells, the
Tax protein acts as a transactivator of cytokine-producing
genes, leading to a state of cell proliferation and the syn-
thesis of various cytokines such as the interleukins IL-1,
IL-2, IL-15, tumor necrosis factor alpha (TNF-α), and in-
terferon gamma (IFN-γ).12,13 The expression of Tax protein
on the surface of CD4+ T cells leads to activation of cyto-
toxic CD8+ T cells, which may destroy cells infected by
the virus but also may contribute to an increase in the se-
cretion of proinflammatory cytokines.14
Certain subtypes of HTLV-I have been reported to be
associated with myelopathy.15 In this context, it is possi-
ble that some virus subtypes may have a greater predilec-
tion for the central nervous system (CNS). Moreover, some
studies have shown that the local production of chemokines
such as CXCL9 and CXCL10 may recruit activated T cells,
which after crossing the blood-brain barrier become in-
stalled predominantly in the thoracic medulla. The intense
production of cytokines at CNS level would result in tis-
sue damage.16
The majority of infected patients who develop HAM/
TSP are between the ages of 30 and 40 years. Myelopathy
generally evolves insidiously, but causes progressively sig-
nificant damage to the CNS, and more than half of these
individuals become wheelchair-dependent.17 Lower back
pain and paresthesias are common complaints in the ini-
tial stages of the disease, but diagnosis is only reached
when the patient develops a change in gait associated with
weakness and stiffening of the lower limbs (spasticity).
Erectile dysfunction, sphincter disturbances, and urinary
complaints also form part of the clinical picture. Physical
examination registers an increase in lower limb reflex re-
sponses, clonus, and Babinski’s sign. Progressive deterio-
ration in walking leads to the use of aids such as a walk-
ing stick or a wheelchair.3 In some patients, the disease de-
velops in episodes similar to those seen in systemic scle-
rosis with which differential diagnosis has to be made in
some cases.18
Other pathologies have also been described as being as-
sociated with HAM/TSP, such as infective dermatitis, uvei-
tis, polyarthralgia, Sjögren’s syndrome, alveolitis, and peri-
odontitis.
Urinary Symptoms
The most common urinary symptoms are increased uri-
nary frequency, nocturia, urgency, dysuria, hesitancy, strain-
ing to urinate, sensation of incomplete emptying, and incon-
tinence. In patients with classic myelopathy (HAM/TSP), the
great majority report urinary symptoms, such as nocturia
(81.4%), involuntary loss of urine (76.9%), urgency (74.4%),
increased frequency (60.5%), and dysuria (39.5%). When
evaluated regarding their quality of life with respect to their
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urinary symptoms, 81% of patients with HAM/TSP reported
that their quality of life was poor or very poor.19
In the early phases of bladder involvement, storage
symptoms such as nocturia, urgency, and urge incontinence
are more frequent. In later phases of the disease, the pres-
ence of bladder-sphincter dyssynergia leads to urinary void-
ing symptoms such as dysuria, hesitancy, straining to uri-
nate, and sensation of incomplete voiding,20 making inter-
mittent bladder catheterization necessary. Some studies
based on small series and case reports have suggested that
urinary symptoms may constitute early manifestations of
HTLV-I infection and may be the first sign of myelopathy.
They may, therefore, be documented prior to the clinical
neurological manifestations.21 This fact has led us to inves-
tigate the frequency of urinary symptoms in individuals in-
fected by HTLV-I who do not have HAM/TSP. Table 1
shows the frequency of symptoms in patients with HAM/
TSP, and in HTLV-I carriers divided in 2 subgroups: those
who had EDSS = 0 and those who had EDSS between 0.5
and 2. Note that the frequency of symptoms such as noc-
turia, frequency, dysuria, and urinary loss increases signifi-
cantly as the degree of autonomy decreases as established
by the Kurtzke scale (EDSS) in asymptomatic HTLV-I car-
riers (EDSS = 0) compared to oligosymptomatic patients
(EDSS > 0 and < 2) and patients with myelopathy-HAM/
TSP (EDSS ≥ 2), in a group of 218 patients.19 As impor-
tant as the high frequency of urinary complaints is the fact
that the type of complaints was similar to those described
in patients with HAM/TSP. This suggests the existence of
a neurogenic bladder prior to the observation of other signs
and symptoms that the medulla has been affected.21 These
data show that neurogenic bladder symptoms commonly
seen in patients with HAM/TSP also constitute frequent
complaints in HTLV-I carriers. It is possible that these
manifestations may represent a subclinical form of my-
elopathy and that some of these patients may go on to de-
velop classic myelopathy.
Although frequency and nocturia are the most common
urinary complaints, urinary incontinence is the symptom
that causes the most profound effect on patients. Urinary
incontinence may occur as a result of detrusor overactivity,
low functional capacity, or stress incontinence due to
hypermobility of the bladder neck or sphincter insuffi-
ciency. In a later phase, detrusor failure occurs with
hypocontractility, high post-micturitional residue, and are-
flexia.20,22 As many of these patients use antidepressant
medication for the management of chronic pain, it is im-
portant to rule out the influence of these drugs on the de-
trusor muscle and urinary sphincter.
Treatment of bladder storage and voiding symptoms
depends on the clinical status of the patient and the
urodynamic findings. The use of anticholinergic medica-
tions such as propantheline bromide,23 oxybutynin, and
tolterodine may reduce urinary frequency and leakage re-
sulting from detrusor overactivity. Patients with frequent
urinary leakage, bladder/sphincter dyssynergia, or detrusor
failure should undergo early bladder catheterization to pro-
tect the upper urinary tract and minimize leakage.
Since the urological manifestations presented by indi-
viduals infected by HTLV-I may be similar to those present
in individuals with urinary tract infections (UTIs), an epi-
demiological, cohort study was carried out, based on in-
formation on urinary complaints but without carrying out
urine culture.24 Findings from this study showed urinary
infection to be more frequent in HTLV-I seropositive pa-
tients than in seronegative controls, with an incidence ra-
tio (IR) of 1.82 for kidney and bladder infection in HTLV-
I carriers and 1.55 for patients infected by HTLV-II com-
pared with seronegative controls.24 Since urine culture was
not carried out in this study, it is possible that a large
number of these patients did not have a urinary infection
but rather, urological complaints secondary to the medulla
and bladder involvement seen in cases of HTLV-I infec-
tion. Nevertheless, HTLV-I-infected individuals would also
be expected to have a higher frequency of urinary infec-
tions due to bladder dysfunction. In fact, in a series of 115
patients studied in our institution, urine culture-documented
UTIs were observed in 14.7%. While the prevalence of UTI
in asymptomatic carriers was 8.1%, in those with myelopa-
thy, 43.3% had a positive urine culture.25
Urodynamic Evaluation
Urodynamic study is an important tool for the evalua-
Table 1 - Urinary symptoms in patients with HTLV-I
Variable Asymptomatic Subclinical HAM/TSP
carriers myelopathy EDSS ≥ 2
EDSS = 0 EDSS > 0
and < 2
Nocturia
No 82.4% 60% 18.6%
Yes 17.6% 40% 81.4%
Incontinence
No 86.6% 72.7% 23.6%
Yes 13.3% 27.3% 76.9%
Frequency
No 92.4% 76.4% 39.5%
Yes 7.6% 23.6% 60.5%
Urgency
No 91.6% 76.4% 25.6%
Yes 8.4% 23.6% 74.4%
Dysuria
No 92.4% 85.5% 60.5%
Yes 7.6% 14.5% 39.5%
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tion of urinary dysfunction and is capable of detecting sig-
nificant abnormalities in patients with HAM/TSP. The
urodynamic findings in 4 different studies in patients with
HAM/TSP are summarized in Table 2. The most frequent
urodynamic finding in those patients is overactive detru-
sor, first described in 1989.26 Cystometry, performed to
evaluate patients in 2 studies carried out in Brazil, detected
detrusor overactivity in 50%27 and 80.76%28 of patients, re-
spectively. Nevertheless, in a study carried out in Japan,
detrusor hypoactivity was the principal finding in the
urodynamic evaluation.10 Bladder-sphincter dyssynergia is
also a frequent finding, detected in 29% to 34% of pa-
tients.10,27 It should be emphasized that many patients with
dyssynergia are also found to have detrusor overactivity at
cystometry. We have also documented these urodynamic
disorders in a sample of HTLV-I carriers who had urinary
manifestations but do not fulfill the criteria for HAM/TSP.
Erectile Dysfunction
Erectile dysfunction (ED) is another condition that is
very frequently found in patients with myelopathy. Never-
theless, despite its high prevalence, a literature search failed
to find any publication on the subject in indexed journals.
In a study carried out in our institution, we administered a
questionnaire on sexual and erectile dysfunction and re-
corded a high prevalence of ED, with a global prevalence
of 40.5% in a group of 79 patients, and a prevalence of
88.2% among those with HAM/TSP. Moreover, in patients
without the formal criteria for diagnosis of HAM/TSP
(EDSS between 0.5 and 2), a greater prevalence of ED was
found compared to carriers with EDSS = 0. These results
were similar to findings in the group of patients with HAM/
TSP, suggesting that in many patients, ED may be an early
or initial manifestation of myelopathy.29 In those individu-
als with ED but without HAM/TSP, discrete alterations may
be seen in neurological status, as well as sphincter dysfunc-
tion and/or an increase in tendinous reflexes. The preva-
lence ratio of ED in the group of asymptomatic HTLV-I
carriers with EDSS = 0 and the group with EDSS between
0.5 and 2 was 27.1.29
There has been a case report on a patient in whom ED
manifested as the first symptom of HAM/TSP.30 In the
evaluation of HTLV-I seropositive men, we observed some
cases of patients who develop severe ED at a young age,
in most cases prior to serological diagnosis of HTLV. Some
of these individuals go on to develop HAM/TSP, and this
has been the target of intense research in our institute, since
these patients may have early immunological responses.
The findings presented here reinforce the concept that
urological manifestations, both urinary and sexual, may
represent an earlier stage of the development of HAM/TSP,
and urologists in regions in which HTLV-I is endemic
should be alerted to this possibility. Although in many cases
ED is severe, we have achieved excellent erectile response
in clinical practice with the use of phosphodiesterase type
5 inhibitors (sildenafil, tadalafil, and vardenafil) in patients
who have had no sexual activity for months due to lack of
an erection sufficient for penetration.
CONCLUSIONS
Urinary symptoms are very common in HTLV-I carri-
ers. Nocturia, increased frequency, detrusor overactivity,
urinary incontinence, bladder-sphincter dyssynergia, and
urinary infections as well as ED are the most common find-
ings in this group of patients. It is important to add that
such urinary tract symptoms and ED may represent the ear-
liest signs of myelopathy. Therefore, patients in geographi-
cal regions with a high prevalence of HTLV having ED and/
or detrusor overactivity of undetermined cause should be
investigated with regard to the possibility of HTLV-I in-
fection. Moreover, all urologists should be familiar with
HAM/TSP, especially those living in regions that are en-
demic for HTLV-I, because early intervention in the course
of this viral disease improves the quality of life of patients
and may prevent more severe urinary tract lesions.
Table 2 - Urodynamic findings in patients with HAM/TSP*
Walton Lima Mori Castro
1993 2002 2004 2006
No. of patients 5 26 32 34
Detrusor overactivity 100% 80.7% 28.1% 50%
Detrusor hypoactivity 0% 3.8% 65.6% 8.8%
Bladder-sphincter 80% 34.6% 34.3% 29.4%
dyssynergia
Normal 0% 15.4% 6.25% 5.9%
*In some studies, the percentages may not add up to 100% due to an overlap
of data or data not shown in this table. Only the urodynamic data of patients
with HAM/TSP are shown in this table.
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RESUMO
Oliveira P, Castro NM de, Carvalho EM. Manifestações
urinárias e sexuais em pacientes infectados pelo HTLV-I.
Clinics. 2007;62(2):191-6.
O HTLV-1 é considerado um vírus de baixa morbidade sen-
do a mielopatia associada ao HTLV-1 (HAM/TSP) e a
leucemia / linfoma de células T do adulto (ATL) as prin-
cipais doenças associadas à infecção viral, observados em
menos de 5% dos indivíduos infectados. Manifestações
urinárias são freqüentes em pacientes com mielopatia, e
representadas principalmente por noctúria, polaciúria, ur-
gência e incontinência urinária, embora a importância des-
tas alterações, e a correlação com a patologia medular não
tem sido devidamente estudada. Nesta revisão enfatizamos
a elevada freqüência de queixas urinárias e sexuais em pa-
cientes, não apenas os portadores de mielopatias, mas tam-
bém em indivíduos considerados como portadores
assintomáticos do HTLV-I. Hiperatividade detrusora e
dissinergia vesico-esfincteriana são as manifestações
urodinâmicas mais freqüentes. A documentação de quei-
xas urinárias e os achados urodinâmicos observados em in-
divíduos considerados portadores assintomáticos são seme-
lhantes aos detectados em pacientes com mielopatia dão
suporte à hipótese que alterações urinárias possam repre-
sentar uma forma oligossintomática da HAM/TSP.
Disfunção eréctil é freqüentemente observada em pacien-
tes infectados pelo HTLV-1, com ou sem mielopatia. In-
fecção do trato urinário também tem elevada prevalência
nestes pacientes. A despeito da ausência de um tratamento
efetivo da mielopatia, o uso de anticolinérgicos e de
inibidores da fosfodiesterase tipo 5 podem melhorar as
queixas urinárias e a disfunção eréctil destes pacientes.
UNITERMOS: HTLV. Disfunção eréctil. Impotencia. In-
fecção urinária. Bexiga. Urodinâmica.
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